Prodia and FKIK Unsoed Extend Collaboration

PURWOKERTO, 22 APRIL 2019 - Prodia and the Faculty of Medicine and Health Sciences (FKIK) of Universitas Jenderal Soedirman (Unsoed) extend their collaboration in educational and research fields, especially in clinical laboratories. The agreement on collaboration extension was signed by the Dean of FKIK Unsoed Dr. dr. Fitranto Arjadi, M. Kes and the Regional Head of Central Java of PT Prodia Widyahusada Tbk Endang Hariyani in the FKIK UNSOED. Prodia has been collaborating with the FKIK UNSOED since 2010.

From the every first, Prodia has been committed to realizing its vision to be the "Centre of Excellence" through the collaborations with several institutions on education, research, and community services. The FKIK UNSOED hopes this collaboration program can mutually strengthen and generate Human Resources excelling in the fields of health and enrich pedagogic science, specifically those related to clinical laboratory.

The collaborations conducted by Prodia and the FKIK UNSOED are the transfer of knowledge in the form of researches related to critical factors in pre-analytical, analytical, and post-analytical examinations, the latest biomarker trends for research (diabetes mellitus, atherosclerosis, cancer, hematology, infectious diseases, kidney, hypertension, etc.), and research methodology (selection of hypothesis/statistical tests); as resource persons in clinical laboratory management (quality control and stabilization, ISO accreditation process, laboratory management); as guest lecturers in subjects related to medical laboratories, biomedicine, and pathobiology of diseases (molecular biology, stem cell, pathobiology of diseases); internship program for students; and research collaboration.

Prodia has been supporting the research since 1991. Up to present, Prodia has assisted more than 3,500 researches and worked on more than 437 new tests for the research. Prodia has also collaborated with 33 renowned universities in Indonesia consisting of 31 Faculties of Medicine, including the FK of UNILA, 1 Institute of Science and Technology, and 1 Faculty of Pharmacy. These collaborations are conducted to enhance the educational activities and researches, especially in the biomedical field in Indonesia.

Additionally, Prodia has provided some newest information in medical science and laboratory for doctors, researchers, scholars, and people in general through Forum Diagnosticum, Laboratory Information, and The Indonesian Biomedical Journal, seminar or talk show, scientific discussion, and medical workshop.

In the field of laboratory and wellness clinic, Prodia has been conducting test development and service innovations. For instance, Prodia is currently developing a gene-based test, i.e. Prodia Genomics. The Genomic Tests developed include NIPT-Prosafe to determine the risk of chromosomal abnormalities in the fetus, CArisk to find out the risk factors for cancer, DIArisk to assess the risk of diabetes, and nutrigenomics to identify the appropriate nutritional intake and types of exercise for each individual. Regarding the service innovations, Prodia currently has provided the Contact Prodia service on 1500-830 and an online personal assistant Ask Prodia (TANIA). TANIA can be accessed by anyone, especially Prodia customers, anytime and anywhere online, through LINE: @prodia.id, Telegram: @prodia.id, Facebook Messenger: @prodia.id, and Prodia Website: www.prodia.co.id.

 ***

About PT Prodia Widyahusada Tbk.

Prodia Clinical Laboratory was initially established in Solo on 7 May 1973 by a group of idealist pharmacists. Mr. Andi Widjaja along with the other founders have been committed to present the best test results with wholehearted services.

As the market leader, since 2012 Prodia has been the only laboratory and clinic in Indonesia accredited by the College of American Pathologists (CAP). It implies that the quality of the test result from Prodia’s laboratory is equal to those of international laboratories.

On 7 December 2016, the Indonesia Stock Exchange officially listed the initial public offering of Prodia as the 15th issuer in 2016, with the ticker symbol “PRDA”. In that corporate action, Prodia offered 187,5 million shares. Accordingly, the fund raised from the Company’s initial public offering (IPO) was Rp1.22 trillion.

Currently, Prodia has had the service network that incorporates 295 outlets, consisting of 148 clinical laboratories across 34 provinces and 124 cities in Indonesia, Prodia Health Care (PHC) - a personalized medicine-based wellness clinic - and specialty clinics, including Prodia Children’s Health Centre (PCHC), Prodia Women’s Health Centre (PWHC), and Prodia Senior Health Centre (PSHC).

Prodia always develops the latest medical examinations and completes types of tests and medical examination panels in order to serve the increasing needs of health checks in Indonesia. Currently, there are approximately 800 medical check-up tests carried out solely by Prodia.

For further information, please contact:

Reskia Dwi Lestari                                                                                                                                                                                     
Marketing Communications Manager
PT Prodia Widyahusada Tbk            
Ph.          +62-21 3144182 ext. 3768
E-mail     marcomm@prodia.co.id